Keser Zafer, Francisco Gerard E
Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center (UTHealth), The NeuroRecovery Research Center Houston, TIRR Memorial Hermann, Houston, 1333B Moursund Street, Room 126, Houston, TX 77030, USA.
Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center (UTHealth), The NeuroRecovery Research Center Houston, TIRR Memorial Hermann, Houston, 1333 Moursund Street, Suite E-108, Houston, TX 77030, USA.
Phys Med Rehabil Clin N Am. 2015 Nov;26(4):671-89. doi: 10.1016/j.pmr.2015.06.009.
Almost 7 million adult Americans have had a stroke. There is a growing need for more effective treatment options as add-ons to conventional therapies. This article summarizes the published literature for pharmacologic agents used for the enhancement of motor and speech recovery after stroke. Amphetamine, levodopa, selective serotonin reuptake inhibitors, and piracetam were the most commonly used drugs. Pharmacologic augmentation of stroke motor and speech recovery seems promising but systematic, adequately powered, randomized, and double-blind clinical trials are needed. At this point, the use of these pharmacologic agents is not supported by class I evidence.
近700万美国成年人曾患中风。作为传统疗法的补充，对更有效治疗方案的需求日益增长。本文总结了已发表的关于用于促进中风后运动和言语恢复的药物制剂的文献。苯丙胺、左旋多巴、选择性5-羟色胺再摄取抑制剂和吡拉西坦是最常用的药物。药物增强中风后的运动和言语恢复似乎前景光明，但需要系统的、有足够效力的、随机的和双盲的临床试验。目前，这些药物制剂的使用尚无I类证据支持。
